Exploration of Targeted Anti-tumor Therapy

Home
/
Exploration of Targeted Anti-tumor Therapy
/
Articles
/
Table 2

From: FGFR3 gene alteration and protein expression in upper urinary tract carcinoma: unsuitability of ureteroscopic biopsy specimens for FGFR3 RNA testing

Table 2. A list of 8 patients harboring FGFR3 alteration in RNU specimens: comparison between paired URS and RNU specimens.

Case ID	Age (yo)	Sex	Archival specimen age	Diagnostic URS biopsy specimen			RNU specimen
Case ID	Age (yo)	Sex	Archival specimen age	Tumor grade	FGFR3 RNA test	FGFR3 IHC H-score	Pathological T (pT) category and tumor grade	FGFR3 RNA test	FGFR3 IHC H-score
1	68	Male	6	High-grade	Test failure	60	pTa low-grade	Y373C	180
2	73	Male	5	Low-grade	Test failure	160	pTa low-grade	Y373C	240
3	55	Male	4	Low-grade	Test failure	100	pT3 high-grade	S249C	100
4	62	Male	4	High-grade	Test failure	210	pTa low-grade	S249C	270
5	59	Male	2	Undefined	Test failure	140	pT2 high-grade	R248C	300
6	69	Male	1	High-grade	Test failure	80	pT2 high-grade	FGFR3::TACC3v3	140
7	74	Female	1	High-grade	No alteration	180	pT3 high-grade	Y373C	210
8	81	Male	1	High-grade	S249C	270	pT1 high-grade	S249C	300

Return to article view

FGFR3: fibroblast growth factor receptor 3; H-score: histochemical scoring method; IHC: immunohistochemical; RNU: radical nephroureterectomy; URS: ureteroscopic; yo: years old.

Declarations

Acknowledgments

The clinicopathological statistics are based on the results or data contributed by many patients, urologists, and radiologists, who are not listed as co-authors.

Author contributions

MM: Conceptualization, Data curation, Formal analysis, Investigation, Funding acquisition, Visualization, Writing—original draft. YO: Formal analysis, Investigation, Methodology. NN and SO: Formal analysis, Investigation, Methodology, Visualization, Funding acquisition. KM, TS, TO, and KI: Formal analysis, Investigation. KF: Project administration, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

Makito Miyake and Yuki Oda, who are the Guest Editors of Exploration of Targeted Anti-tumor Therapy, had no involvement in the decision-making or the review process of this manuscript. The other authors declare no conflicts of interest.

Ethical approval

This study was approved by the Nara Medical University Ethics Committee (reference protocol ID: 2891) and conducted in accordance with the principles of the Declaration of Helsinki.

Consent to participate

Informed consent was obtained from all participants through posters and/or websites using the opt-out method.

Consent to publication

Not applicable.

Availability of data and materials

The data underlying this article will be shared on reasonable request to the corresponding author.

Funding

This work was supported by JSPS KAKENHI grant numbers 23K08720 (Makito Miyake), 24K10142 (Makito Miyake), and 25K12581 (Nobutaka Nishimura). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Miyake M. Impact of durable response of first-line systemic treatment for patients with locally advanced or metastatic urothelial carcinoma: data update of EV-302/KEYNOTE-A39 trial. Transl Androl Urol. 2025;14:3799–805. [DOI] [PubMed] [PMC]

Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2023;389:1961–71. [DOI]

Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, et al. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor. Mol Cancer Ther. 2017;16:1010–20. [DOI] [PubMed]

Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, et al.; THOR cohort 2 investigators. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. Ann Oncol. 2024;35:107–17. [DOI] [PubMed]

Matsubara N, Loriot Y, Banek S, Valderrama BP, Hwang J, Deprince K, et al. Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with Locally Advanced/Metastatic Urothelial Cancer and Non-muscle-invasive Bladder Cancer: An Analysis of the Global ANNAR Biomarker Study. Eur Urol Oncol. 2025;8:1558–65. [DOI] [PubMed]

Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. Chichester: Wiley; 2017. pp. 196–8.

Miyake M, Miyamoto T, Shimizu T, Ohnishi S, Fujii T, Nishimura N, et al. Tumor expression of Nectin-1-4 and its clinical implication in muscle invasive bladder cancer: An intra-patient variability of Nectin-4 expression. Pathol Res Pract. 2022;237:154072. [DOI] [PubMed]

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, et al. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. Ann Oncol. 2016;27:1311–6. [DOI] [PubMed] [PMC]

Miyake M, Ishii M, Koyama N, Kawashima K, Kodama T, Anai S, et al. 1-tert-Butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a Selective Tyrosine Kinase Inhibitor of Fibroblast Growth Factor Receptor-3 (FGFR3), Inhibits Cell Proliferation of Bladder Cancer Carrying the FGFR3 Gene Mutation along with Up-Regulation of p27/Kip1 and G₁/G₀ Arrest. J Pharmacol Exp Ther. 2010;332:795–802. [DOI]